A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|Residual Disease
Interventions: DRUG: Niraparib|RADIATION: Radiation Therapy
Sponsor: Massachusetts General Hospital
Collaborators: Tesaro, Inc.